Lomucin Trial Ends Due to Lack of Efficacy
| 2 min read

Cystic Fibrosis Foundation Therapeutics, Inc. and Genaera Corporation have agreed to discontinue the Phase 2 clinical evaluation of Lomucin for CF because it was deemed unlikely that continued enrollment of patients into the study would ever result in the drug being proven effective.

The study was terminated based on a recommendation by Genaera to the study's Data Monitoring Committee. The committee identified no safety concerns in their review of the data and agreed that the study should end.

About two-thirds of the drugs that make it past Phase 1 testing continue on to Phase 2 trials. Safety and effectiveness are examined in these trials. In most Phase 2 trials, one group of volunteers may be given the experimental drug while another "control" group will receive a placebo. A Phase 2 trial does not give a final assessment of whether or not a particular drug will successfully treat an illness, although many patients may report experiencing some therapeutic benefits.

Currently, there are nearly 30 potential therapies in the CF Foundation's drug development pipeline. It is estimated that only one in five new drugs that enter clinical trials will become an approved therapy for patients. This is why the Foundation must continuously feed the drug development pipeline to better the success for all people with CF.

Share this article
Recent news
CF Foundation Grateful for Continued Access to Trikafta in Colorado After Prescription Drug Affordability Board’s Ruling
News | 2 min read
CF Foundation Invests Up to $3 Million in ViaNautis Bio to Explore a New Method to Deliver Genetic Therapies to People With CF
News | 2 min read
CF Foundation Formalizes Final Set of Recommendations From External Racial Justice Working Group
News | 4 min read
You might also be interested in...
Stay up to date with The Foundation

Sign up for our newsletter to get all of the latest news from The Foundation right in your inbox.